Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2

Cancer Letters

Volumn 333, Issue 2, 2013, Pages 187-193

  Hrstka, Roman ^a   Murray, Euan ^a,b   Brychtova, Veronika ^a   Fabian, Pavel ^a   Hupp, Ted R ^a,b   Vojtesek, Borivoj ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

AGR2; AKT; Breast cancer; PDPK1; Tamoxifen

Indexed keywords

MICRORNA; ONCOPROTEIN; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PRO METASTATIC PROTEIN ANTERIOR GRADIENT 2; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; SMALL INTERFERING RNA; TAMOXIFEN; TETRANDRINE; TRICIRIBINE; UNCLASSIFIED DRUG;

AGR2 GENE; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN METABOLISM; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR CELL;

ANTINEOPLASTIC AGENTS, HORMONAL; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MICRORNAS; MOLECULAR SEQUENCE DATA; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIBONUCLEOSIDES; SERINE; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84876718505     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.034     Document Type: Article

References (27)

1. Aberger F., Weidinger G., Grunz H., Richter K. Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2. Mech. Dev. 1998, 72:115-130.
2. Kumar A., Godwin J.W., Gates P.B., Garza-Garcia A.A., Brockes J.P. Molecular basis for the nerve dependence of limb regeneration in an adult vertebrate. Science 2007, 318:772-777.
3. Park S.W., Zhen G., Verhaeghe C., Nakagami Y., Nguyenvu L.T., Barczak A.J., Killeen N., Erle D.J. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc. Natl. Acad. Sci. USA 2009, 106:6950-6955.
4. Zheng W., Rosenstiel P., Huse K., Sina C., Valentonyte R., Mah N., Zeitlmann L., Grosse J., Ruf N., Nurnberg P., Costello C.M., Onnie C., Mathew C., Platzer M., Schreiber S., Hampe J. Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. Genes Immun. 2006, 7:11-18.
5. Schroeder B.W., Verhaeghe C., Park S.W., Nguyenvu L.T., Huang X., Zhen G., Erle D.J. AGR2 is induced in asthma and promotes allergen-induced mucin overproduction. Am. J. Respir. Cell Mol. Biol. 2012, 47:178-185.
6. Innes H.E., Liu D., Barraclough R., Davies M.P., O'Neill P.A., Platt-Higgins A., de Silva Rudland S., Sibson D.R., Rudland P.S. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br. J. Cancer 2006, 94:1057-1065.
7. Liu D., Rudland P.S., Sibson D.R., Platt-Higgins A., Barraclough R. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res. 2005, 65:3796-3805.
8. Wang Z., Hao Y., Lowe A.W. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res. 2008, 68:492-497.
9. Pohler E., Craig A.L., Cotton J., Lawrie L., Dillon J.F., Ross P., Kernohan N., Hupp T.R. The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol. Cell. Proteomics 2004, 3:534-547.
10. Dong A., Gupta A., Pai R.K., Tun M., Lowe A.W. The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through Hippo pathway co-activator YAP1 activation. J. Biol. Chem. 2011, 286:18301-18310.
11. Brychtova V., Vojtesek B., Hrstka R. Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett. 2011, 304:1-7.
12. Thompson D.A., Weigel R.J. HAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem. Biophys. Res. Commun. 1998, 251:111-116.
13. Lee S., Bang S., Song K., Lee I. Differential expression in normal-adenoma-carcinoma sequence suggests complex molecular carcinogenesis in colon. Oncol. Rep. 2006, 16:747-754.
14. Zhu H., Lam D.C., Han K.C., Tin V.P., Suen W.S., Wang E., Lam W.K., Cai W.W., Chung L.P., Wong M.P. High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines. Cancer Lett. 2007, 245:303-314.
15. Hrstka R., Nenutil R., Fourtouna A., Maslon M.M., Naughton C., Langdon S., Murray E., Larionov A., Petrakova K., Muller P., Dixon M.J., Hupp T.R., Vojtesek B. The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene 2010, 29:4838-4847.
16. Zhang Y., Forootan S.S., Liu D., Barraclough R., Foster C.S., Rudland P.S., Ke Y. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis. 2007, 10:293-300.
17. Gray T.A., MacLaine N.J., Michie C.O., Bouchalova P., Murray E., Howie J., Hrstka R., Maslon M.M., Nenutil R., Vojtesek B., Langdon S., Hayward L., Gourley C., Hupp T.R. Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models. J. Immunol. Methods 2012, 378:20-32.
18. Hengel S.M., Murray E., Langdon S., Hayward L., O'Donoghue J., Panchaud A., Hupp T., Goodlett D.R. Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance. J. Proteome Res. 2011, 10:4567-4578.
19. Chevet E., Fessart D., Delom F., Mulot A., Vojtesek B., Hrstka R., Murray E., Gray T., Hupp T. Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development. Oncogene 2012.
20. Fletcher G.C., Patel S., Tyson K., Adam P.J., Schenker M., Loader J.A., Daviet L., Legrain P., Parekh R., Harris A.L., Terrett J.A. HAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br. J. Cancer 2003, 88:579-585.
21. Iorns E., Lord C.J., Ashworth A. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem. J. 2009, 417:361-370.
22. Kirkegaard T., Witton C.J., McGlynn L.M., Tovey S.M., Dunne B., Lyon A., Bartlett J.M. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J. Pathol. 2005, 207:139-146.
23. Tokunaga E., Kimura Y., Oki E., Ueda N., Futatsugi M., Mashino K., Yamamoto M., Ikebe M., Kakeji Y., Baba H., Maehara Y. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int. J. Cancer 2006, 118:284-289.
24. Jensen E.V., Jordan V.C. The estrogen receptor: a model for molecular medicine. Clin. Cancer Res. 2003, 9:1980-1989.
25. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet 351 (1998) 1451-1467.
26. Massarweh S., Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr. Relat. Cancer 2006, 13(Suppl. 1):S15-24.
27. Arpino G., Green S.J., Allred D.C., Lew D., Martino S., Osborne C.K., Elledge R.M. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin. Cancer Res. 2004, 10:5670-5676.